Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Phase 3 trials with larger populations may show different rates
Identifying patient-specific factors that predict responsiveness to VNS could help tailor treatments and maximize efficacy
Gulp down the tablet
Histological endpoints Histological endpoints to assess response to a therapeutic intervention can be broadly divided into those meeting a numerical reduction in one of two accepted scoring systems: NAFLD Activity Score (NAS) or Steatosis Activity and Fibrosis (SAF) score or the resolution of NASH as determined by a qualified hepatopathologist.[35], [36] When change in the NAS is used as a primary outcome, it is recommended that 2 point improvement in total score be achieved with contribution from multiple parameters of the NAS, alongside no worsening of fibrosis.37 For trials evaluating resolution of NASH, this is defined as a complete resolution of hepatocyte ballooning, with inflammation scores of 0 or 1, in addition to no worsening of fibrosis, though there is no specific requirement regarding change in steatosis
Topped with a crispy, almond flour coating, its a delicious, lighter version of a Thanksgiving classic
R.DuongT
